Has Mohan Sadana, MD received payments from drug or device companies?

Yes. Drug and device makers reported $1,929 in general payments to Mohan Sadana, MD across 21 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Mohan Sadana, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Mohan Sadana, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Mohan Sadana, MD

Plastic Surgery · Warsaw, NYNPI 1750345104

Payments from drug & device makers

What this record shows

9 manufacturers reported payments, led by Solventum Corporation at 59.7% of the total. Reporting peaked in 2024 at $1,151 and has fallen 98.2% since, to $21 in 2025.

$1,929in general payments, 2019–2025

Across 21 payments — averaging $91.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Solventum Corporation$1K
Amgen$342
Novo Nordisk$120
Johnson & Johnson$118
GSK$59
Teva Pharmaceuticals USA, Inc.$43
plus $96 from 3 others

What the payments were for

Travel & lodging$89546%
Food & beverage$1,03454%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Solventum Corporation	7	$1,151
Amgen	6	$342
Novo Nordisk	1	$120
Johnson & Johnson	2	$118
GSK	1	$59
Teva Pharmaceuticals USA, Inc.	1	$43
Lilly USA, LLC	1	$38
Boehringer Ingelheim	1	$37
Kerecis Limited	1	$21

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,929 in reported general payments places this provider in the 55th percentile of 363 plastic surgery providers in New York.

See all plastic surgery providers in New York →

Medicare billing

Part B allowed, 2024

$144,260

Medicare patients

Services billed

1,641

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other plastic surgery in Warsaw

Sachin ShridharaniNew York$1.1M
Scot GlasbergNew York$959K
Nolan KarpNew York$900K
Michael LacquaBrooklyn$865K
Sydney ColemanNew York$729K
David RapaportNew York$578K
Richard SwiftNew York$487K
Michael KaneNew York$250K
Z LorencNew York$225K
Joseph DayanNew York$123K

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →